Similar Search Results

Group living for elderly patients with dementia -- A cost analysis

Svensson, Marianne; Edebalk, Per Gunnar; Persson, Ulf - In: Health Policy 38 (1996) 2, pp. 83-100

Persistent link: https://www.econbiz.de/10005516183

The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden

Willis, Michael; Svensson, Marianne; Löthgren, Mickael; … - In: The European Journal of Health Economics 11 (2010) 6, pp. 585-594

Persistent link: https://www.econbiz.de/10008775862

EuroQol(c): health-related quality of life measurement. Results of the Swedish questionnaire exercise

Brooks, Richard G.; Jendteg, Stefan; Lindgren, Bjorn; … - In: Health Policy 18 (1991) 1, pp. 37-48

Persistent link: https://www.econbiz.de/10005516248

Long-term follow-up and consequences for severe road traffic injuries--treatment costs and health impairment in Sweden in the 1960s and the 1990s

Maraste, Pia; Persson, Ulf; Berntman, Monica - In: Health Policy 66 (2003) 2, pp. 147-158

Persistent link: https://www.econbiz.de/10005516409

Retrospective incremental cost analysis of a hospital-based COPD Disease Management Programme in Sweden

Tunsater, Alf; Moutakis, Mikael; Borg, Sixten; Persson, Ulf - In: Health Policy 81 (2007) 2-3, pp. 309-319

Persistent link: https://www.econbiz.de/10005520147

Scope and scale insensitivities in a contingent valuation study of risk reductions

Norinder, Anna; Hjalte, Krister; Persson, Ulf - In: Health Policy 57 (2001) 2, pp. 141-153

Persistent link: https://www.econbiz.de/10005520441

Delphi approach to select rare diseases for a European representative survey. The BURQOL-RD study

Linertová, Renata; Serrano-Aguilar, Pedro; … - In: Health Policy 108 (2012) 1, pp. 19-26

The BURQOL-RD project is intended to develop a disease based model capable of quantifying the socio-economic burden and health-related quality of life for patients with rare diseases (RDs) and their caregivers in Europe. We described the methodology used to select a set of 10 RDs to be...

Persistent link: https://www.econbiz.de/10011048306

A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing

Persson, Ulf; Svensson, Johanna; Pettersson, Billie - In: Applied Health Economics and Health Policy 10 (2012) 4, pp. 217-225

Sweden has experienced a national value-based pricing (VBP) system for innovative outpatient drugs operated by the Pharmaceutical Benefits Board — LFN (now called the Dental and Pharmaceutical Benefits agency — TLV) since 2002. VBP has the character of a monopoly system, leading to...

Persistent link: https://www.econbiz.de/10011000768

Authors’ Reply to Godman and Gustafsson: “A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing”

Persson, Ulf; Svensson, Johanna; Pettersson, Billie - In: Applied Health Economics and Health Policy 11 (2013) 1, pp. 83-84

Persistent link: https://www.econbiz.de/10011000861

Cost Effectiveness of Becaplermin in the Treatment of Diabetic Foot Ulcers in Four European Countries

Ghatnekar, Ola; Persson, Ulf; Willis, Michael; … - In: PharmacoEconomics 19 (2001) 7, pp. 767-778

Objective: The primary objective of this study was to estimate the cost effectiveness of treating diabetic foot ulcers with becaplermin (Regranex(R)) plus good wound care (GWC) compared with GWC alone in a variety of European healthcare settings. A secondary objective was to analyse the effect...

Persistent link: https://www.econbiz.de/10005449166